drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous gene-modified cellular therapy)
drug_description
Patient-derived T cells genetically engineered ex vivo to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on myeloma cells; infused after lymphodepletion to expand and mediate antigen-specific cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are collected and genetically engineered ex vivo to express a chimeric antigen receptor that recognizes BCMA (TNFRSF17) on myeloma cells. Following lymphodepletion, the CAR‑T cells are infused; antigen binding activates the CAR signaling domains (CD3ζ with costimulation), driving T‑cell expansion, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of BCMA‑expressing malignant plasma cells.
drug_name
Autologous BCMA-directed CAR-T cells
nct_id_drug_ref
NCT06581640